U.S. Markets open in 1 hr 16 mins
  • S&P Futures

    4,396.25
    +1.75 (+0.04%)
     
  • Dow Futures

    34,936.00
    -17.00 (-0.05%)
     
  • Nasdaq Futures

    14,994.25
    +46.50 (+0.31%)
     
  • Russell 2000 Futures

    2,201.40
    +14.70 (+0.67%)
     
  • Crude Oil

    71.96
    +0.31 (+0.43%)
     
  • Gold

    1,795.40
    -4.40 (-0.24%)
     
  • Silver

    24.77
    +0.12 (+0.49%)
     
  • EUR/USD

    1.1811
    -0.0015 (-0.1299%)
     
  • 10-Yr Bond

    1.2340
    0.0000 (0.00%)
     
  • Vix

    18.91
    +1.33 (+7.57%)
     
  • GBP/USD

    1.3874
    -0.0005 (-0.0361%)
     
  • USD/JPY

    110.0620
    +0.2950 (+0.2687%)
     
  • BTC-USD

    40,616.97
    +2,688.88 (+7.09%)
     
  • CMC Crypto 200

    947.96
    +71.73 (+8.19%)
     
  • FTSE 100

    7,007.95
    +11.87 (+0.17%)
     
  • Nikkei 225

    27,581.66
    -388.56 (-1.39%)
     

Long-awaited Novavax's COVID-19 Vaccine Results Hit 90% Efficacy In Pivotal US Trial, 100% Efficacy Against Moderate, Severe Infection

·2 min read
  • Novavax Inc (NASDAQ: NVAX) has finally completed its U.S. Phase 3 trial for its protein-based COVID-19 vaccine candidate.

  • Overall efficacy in the study hit 90.3% across nearly 30,000 patients in the U.S. and Mexico, with a total of 77 cases observed.

  • In the placebo arm, researchers saw 63 cases of COVID-19 compared to 14 in the vaccine group.

  • Novavax reiterated its plans to file for emergency use with the FDA in the third quarter.

  • The company added the vaccine was 100% effective against moderate and severe disease based on ten moderate cases and four severe cases, all in the placebo group.

  • In addition to the topline data, Novavax also said the study hit 93.2% efficacy against variants of concern or interest.

  • The company had sequencing data available for 54 of the 77 cases, with 44 of those turning out to be such variants.

  • Among these participants, 38 cases were seen in the placebo arm compared to six in the vaccine group.

  • The remaining ten sequenced cases were “other variants,” Novavax said.

  • Among high-risk individuals, it hit 91% efficacy. 62 cases among those older than 65 or younger than 65 but with comorbidities were reported, compared to 13 in the vaccine arm.

  • Today’s results come in similar to those data, which Novavax previously said had been 96% effective against the original SARS-CoV-2 virus and 86% effective against the Alpha variant first identified in the U.K.

  • Efficacy plunged to 50% in the Beta variant, which first emerged in South Africa.

  • The company also announced promising data on its COVID-19 vaccine candidate, NVX-CoV2373, directed against the Beta (B.1.351) variant.

  • Price Action: NVAX shares are up 7.78% at $226 during the premarket session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.